Brief: Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics
24/06/2025 12:34
June 24 (Reuters) - Lexeo Therapeutics Inc LXEO.O: LEXEO THERAPEUTICS, PERCEPTIVE XONTOGENY VENTURE FUNDS AND VENBIO PARTNERS ANNOUNCE PARTNERSHIP TO ADVANCE NOVEL CARDIAC RNA THERAPEUTICS LEXEO THERAPEUTICS INC: INVESTMENT OF UP TO $40 MILLION FROM PERCEPTIVE XONTOGENY VENTURE FUNDS AND VENBIO PARTNERS Source text: ID:nGNX8td1pG Further company coverage: LXEO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lexeo Therapeutics
See all newsBrief: Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia
Brief: Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
U.S. STOCKS ON THE MOVE-Datadog, Terawulf
Lexeo rises as co sets late-stage trial plan for gene therapy in rare heart disease